Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone by unknown
RESEARCH Open Access
Targeting glutamine metabolism sensitizes
pancreatic cancer to PARP-driven metabolic
catastrophe induced by ß-lapachone
Gaurab Chakrabarti1,2, Zachary R. Moore1,2, Xiuquan Luo1,2, Mariya Ilcheva2, Aktar Ali3, Mahesh Padanad4,
Yunyun Zhou5, Yang Xie5, Sandeep Burma2, Pier P. Scaglioni4, Lewis C. Cantley6, Ralph J. DeBerardinis7,
Alec C. Kimmelman8, Costas A. Lyssiotis9,10* and David A. Boothman1,2*
Abstract
Background: Pancreatic ductal adenocarcinomas (PDA) activate a glutamine-dependent pathway of cytosolic
nicotinamide adenine dinucleotide phosphate (NADPH) production to maintain redox homeostasis and support
proliferation. Enzymes involved in this pathway (GLS1 (mitochondrial glutaminase 1), GOT1 (cytoplasmic glutamate
oxaloacetate transaminase 1), and GOT2 (mitochondrial glutamate oxaloacetate transaminase 2)) are highly upregulated
in PDA, and among these, inhibitors of GLS1 were recently deployed in clinical trials to target anabolic glutamine
metabolism. However, single-agent inhibition of this pathway is cytostatic and unlikely to provide durable benefit in
controlling advanced disease.
Results: Here, we report that reducing NADPH pools by genetically or pharmacologically (bis-2-(5-phenylacetamido-1,2,
4-thiadiazol-2-yl)ethyl sulfide (BPTES) or CB-839) inhibiting glutamine metabolism in mutant Kirsten rat sarcoma viral
oncogene homolog (KRAS) PDA sensitizes cell lines and tumors to ß-lapachone (ß-lap, clinical form ARQ761). ß-Lap is
an NADPH:quinone oxidoreductase (NQO1)-bioactivatable drug that leads to NADPH depletion through high levels of
reactive oxygen species (ROS) from the futile redox cycling of the drug and subsequently nicotinamide
adenine dinucleotide (NAD)+ depletion through poly(ADP ribose) polymerase (PARP) hyperactivation.
NQO1 expression is highly activated by mutant KRAS signaling. As such, ß-lap treatment concurrent with
inhibition of glutamine metabolism in mutant KRAS, NQO1 overexpressing PDA leads to massive redox
imbalance, extensive DNA damage, rapid PARP-mediated NAD+ consumption, and PDA cell death—features
not observed in NQO1-low, wild-type KRAS expressing cells.
Conclusions: This treatment strategy illustrates proof of principle that simultaneously decreasing glutamine
metabolism-dependent tumor anti-oxidant defenses and inducing supra-physiological ROS formation are
tumoricidal and that this rationally designed combination strategy lowers the required doses of both agents in
vitro and in vivo. The non-overlapping specificities of GLS1 inhibitors and ß-lap for PDA tumors afford high tumor
selectivity, while sparing normal tissue.
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Background
Pancreatic ductal adenocarcinoma (PDA) is a recalci-
trant cancer in which patients have <6 % 5-year survival
rates. Mortality from this disease is predicted to be the
second leading cause of cancer-related death by 2020 [1].
PDAs are highly resistant to conventional chemotherapies
[1], and activating mutations in Kirsten rat sarcoma viral
oncogene homolog (KRAS) are present in >95 % of all cases
[2]. Despite significant effort from the pharmaceutical in-
dustry over the past 30 years, KRAS has proven to be a
challenging drug target [3]. An emerging therapeutic ap-
proach is to target alterations in PDA metabolism driven by
mutant KRAS [2, 4–6]. For example, PDA cells generate
the bulk of the ribose used for de novo nucleotide biosyn-
thesis through the non-oxidative arm of the pentose phos-
phate pathway [7]. This KRAS-driven reprogramming of
glucose metabolism bypasses the nicotinamide adenine
dinucleotide phosphate (NADPH)-generating oxidative
arm. To compensate for this rewiring, PDAs utilize glutam-
ine through a GLS1 (mitochondrial glutaminase)-, GOT2
(mitochondrial glutamate oxaloacetate transaminase 2)-,
and GOT1 (cytoplasmic glutamate oxaloacetate transamin-
ase 1)-dependent pathway to support cellular redox balance
in the face of rapid proliferation and growth (Fig. 1a) [2, 8,
9]. This is in contrast to the canonical metabolism of
glutamine-derived glutamate through GLUD1 (glutamate
dehydrogenase 1) to supply carbon backbone to the TCA
cycle. Genetic inhibition of enzymes in this pathway is pro-
foundly growth inhibitory in PDA but does not result in
the induction of a cytotoxic response. These results suggest
that a means to induce redox balance in PDA, concurrent
with inhibition of this KRAS-dependent Gln metabolism
pathway, may provide a means to induce tumor-selective
killing.
Gene name Other cancer types? (p-val) Normal pancreatic tissue? (p-val) 
NQO1 Yes (5.59e-20) Yes (3.46e-08) 
GLS1 Yes (3.61e-05) Yes (1.42e-04) 
GOT1/2 Yes (6.40e-04) Yes (0.003) 
ME1 Yes (0.002) Yes (1.71e-04) 
GLUD1 No Yes (0.002) 
Upregulated in PDA compared to: 
A
B C
Fig. 1 Glutamine metabolism genes are upregulated in PDA. a Glutamine utilization pathway in PDA. Asp aspartate, GSR glutathione-disulfide reductase.
b NQO1 and glutamine metabolism enzymes assessed in patient tumor tissue in PDA versus 17 other cancer types (central columns, “other” cancers include
solid and hematological malignancies) and PDA versus normal pancreatic tissue (right most column). Data were obtained from Oncomine
(www.oncomine.org). c Kaplan–Meier survival curve corrected for multiple comparisons of 45 PDA patients grouped according to high
versus low GOT1:GLUD1 expression assessed using the PROGgene webtool (http://watson.compbio.iupui.edu/chirayu/proggene/database/?url=proggene)
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In an attempt to leverage increased tumor-cell reliance
on glutamine, small molecule inhibitors of GLS1 were
developed (e.g., bis-2-(5-phenylacetamido-1,2,4-thiadia-
zol-2-yl)ethyl sulfide (BPTES), CB-839, compound 968)
[10–12]. GLS1 catalyzes the first step in the PDA glu-
tamine metabolism pathway, converting glutamine to
glutamate (Fig. 1a) [8]. As such, GLS1 inhibition in PDA
cells in culture leads to a block in glutamine metabolism
but, as with the genetic approaches above, lacks cytotox-
icity. Moreover, while GLS1 inhibitors are potent inhibi-
tors of cell proliferation in cell culture models, they have
relatively minor effects on tumor growth in pre-clinical
cancer models as single agents [13–17].
To increase the specificity and efficacy of GLS1 inhibition
in PDA, we combined BPTES or CB-839 with ß-lapachone
(ß-lap), a targeted cancer therapeutic that causes tumor-
selective reactive oxygen species (ROS) formation in an
NADPH:quinone oxidoreductase 1 (NQO1)-specific man-
ner [18]. NQO1 is highly expressed in many types of cancer,
including PDA. In fact, elevated NQO1 expression (≥ten-
fold) has been observed in ~90 % of PDA patient speci-
mens, making PDA an especially appealing target for
therapy using NQO1-bioactivatable drugs, such as ß-lap
[18–21].
ß-Lap is a substrate for two-electron oxidoreduction
by NQO1, an inducible phase II quinone-detoxifying en-
zyme. The resulting hydroquinone form of ß-lap is
highly unstable and spontaneously reacts with oxygen to
revert back to the parent compound, generating two
moles of superoxide per mole NAD(P)H used in the
process [18]. This leads to a futile cycle that occurs rapidly
in NQO1-overexpressing cells resulting in massive ROS for-
mation, oxidative DNA damage, and H2O2-mediated DNA
single-strand breaks (Additional file 1: Figure S1A). In an
attempt to repair this damage, poly(ADP ribose) polymer-
ase (PARP) becomes hyperactivated, generating extensive
free branched poly(ADP ribose) (PAR) polymer levels. The
hyperactivated PARP substantially depletes intracellular
nicotinamide adenine dinucleotide (NAD)+ and adenosine
triphosphate (ATP) pools and ultimately overwhelms the
ability of the DNA repair machinery to repair ß-lap-in-
duced DNA lesions.
The therapeutic window provided by NQO1 expression
(and thus NQO1-mediated bioactivation of ß-lap) has ad-
vanced ß-lap to phase I and Ib clinical trials (ARQ761) [22].
Unfortunately, dose-limiting methemoglobinemia caused
by nonspecific ROS generation at high ß-lap doses some-
what limits the efficacy of ß-lap as monotherapy [22].
Strategies for increasing cancer cell cytotoxicity, while
maintaining NQO1 specificity, could further enhance effi-
cacy of ß-lap for therapy against PDAs.
ß-Lap and GLS1 inhibition have distinct but highly
complementary mechanisms of action. ß-Lap induces
tumor-selective ROS generation specifically in PDA cells
that express high levels of NQO1. GLS1 inhibition primes
PDA cancer cells for death by lowering anti-oxidant pools
derived from glutamine, sensitizing the cell to ROS dam-
age. Here we show, using an in vivo pre-clinical model of
PDA, that the increased dependence of PDA cells on glu-
tamine is specifically targeted by exposure to both drugs.
The use of ß-lap with GLS1 inhibitors results in synergis-
tic NQO1- and PARP-dependent cancer cell death, allow-
ing use of lower doses and shorter treatment times for
both agents.
Results
Glutamine metabolism genes are upregulated in PDA
Enzymes utilized for glutamine metabolism in PDA,
GLS1, GOT1/2, and malic enzyme 1 (ME1) (see pathway,
Fig. 1a), in addition to NQO1, were significantly upregu-
lated in PDA compared to 17 other cancers when assessed
using the Oncomine webtool (Fig. 1b) [8]. This was appar-
ent in both cell lines and tumor samples. In contrast,
GLUD1, which diverts glutamine carbon away from the
GOT2–GOT1–ME1 pathway into an alternate metabolic
pathway, was not upregulated in PDA relative to other
cancer types (Fig. 1a). Additionally, glutamine metabolic
enzymes, NQO1, and GLUD1 were found to be signifi-
cantly upregulated in PDA relative to normal pancreatic
tissue (Fig. 1a). To determine the clinical relevance associ-
ated with the PDA glutamine metabolic pathway relative
to other enzymes involved in glutamine metabolism, we
evaluated the association of individual gene expression
levels with overall survival in the data set that contained
clinical follow-up information [23]. Kaplan–Meier analysis
did not show a significant difference in outcome when pa-
tients were separated into high and low expression levels
of the genes of interest (data not shown). However, when
GOT1 and GOT2 were normalized to GLUD1 expression,
we found that a high GOT1 to GLUD1 or GOT2 to
GLUD1 ratio was significantly associated with poor out-
come (Fig. 1c, Additional file 1: Figure S1B). These data
suggest that gene expression of GOT isoforms are gener-
ally elevated in PDA and have prognostic and functional
significance relative to GLUD1 expression.
Inhibiting glutamine metabolism sensitizes PDA to ß-lap
Given the reliance of PDA on glutamine metabolism for
redox balance, we hypothesized that glutamine deprivation
of NQO1-overexpressing PDA cells would sensitize them to
ß-lap exposure by lowering anti-oxidant defenses and in-
creasing NQO1-induced ROS damage. MiaPaCa2 cells were
grown in Gln-free or Gln-containing (2 mM) media for
16 h and then exposed to ß-lap for 2 h. Short-term Gln
deprivation did not significantly alter clonogenic sur-
vival on its own (Fig. 2a) but did sensitize MiaPaCa2
cells to ß-lap at sub-lethal and higher doses of the drug
(Fig. 2a). To confirm these results, we repeated this
Chakrabarti et al. Cancer & Metabolism  (2015) 3:12 Page 3 of 12
experiment in five other PDA cell lines: ASPC1, MPanc96,
HPAFII, SW1990, and DAN-G (Fig. 2b–f ). Additionally,
we demonstrated that the observed cytotoxicity was
NQO1-dependent, and as addition of the potent NQO1
inhibitor, dicoumarol (DIC), spared cells from lethality
(Fig. 2b–f ) [24–26].
Next, RNAi-mediated knockdown of glutamine metab-
olism enzymes revealed that GLS1, GOT1, and ME1 dra-
matically sensitized MiaPaCa2 and ASPC1 PDA cell lines
to ß-lap, relative to non-targeting control (scramble small
interfering RNA (siScr)) (Fig. 2g–k). Consistent with the
mechanism by which glutamine is metabolized in PDA to
maintain redox balance [8], knockdown of GLUD1 had no
effect on ß-lap sensitivity (Fig. 2i). Sensitization of ß-lap-
treated MiaPaCa2 cells by GLS1 knockdown was rescued
by replenishing metabolic substrates of the glutamine
metabolism pathway that are downstream of the GLS1 re-
action, namely, oxaloacetate (OAA) or cell-permeable
dimethyl malate (Fig. 2j, k). These data indicate that
PDA cells have an increased reliance on glutamine to
generate NADPH (Fig. 1a) in the presence of ß-lap-in-
duced ROS stress.
GLS1 inhibition by BPTES sensitizes PDA to ß-lap in an
NQO1-dependent manner
To pharmacologically replicate the ß-lap sensitization to
inhibition of Gln metabolism, MiaPaCa2 cells were treated
with a sub-lethal dose of the mitochondrial GLS1 inhibi-
tor, BPTES (500 nM, 48 h, Additional file 2: Figure S2)
and then exposed to various doses of ß-lap for 2 h, with or
Fig. 2 Inhibiting glutamine metabolism sensitizes PDA to ß-lap. a Colony formation assay of MiaPaCa2 cells depleted of glutamine for 16 h,
followed by treatment with ß-lap for 2 h. p < 0.01 at 3 μM and p < 0.0001 at 4 μM. b–f Glutamine deprivation experiments with a dose range of
ß-lap in ASPC1, MPanc96, HPAFII, SW1990, and DAN-G PDA cell lines. g ß-lap dose response in MiaPaCa2 cells with knockdown of GLS1. h Western
blots for GLS1, ME1, GOT1, and GLUD1 upon knockdown in MiaPaCa2 cell lines for 48 h using siRNA. i Relative survival of GOT1, GLS1, GLUD1, and
ME1 MiaPaCa2 knockdown cells treated with 2.5 μM ß-lap for 2 h. j, k GLS1 was knocked down in MiaPaCa2, and either 3 mM oxaloacetate (OAA)
or 3 mM dimethyl malate was added for 24 h followed by a 2-h treatment with 2.5 μM ß-lap. Relative survival represents means of CellTiter-Glo
survival assay 48 h after treatment plotted as percentage treated/control (T/C), ±SE from sextuplicate samples. All results were compared using
Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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without DIC (Fig. 3a). BPTES pre-treatment in combin-
ation with ß-lap significantly reduced clonogenic survival
versus ß-lap alone, while addition of DIC spared the
lethality (Fig. 3a). To confirm that our results were due to
inhibition of the glutamine-dependent transamination
pathway and not the alternative glutamine metabolism
pathway through GLUD1 , we pre-treated MiaPaCa2 cells
with epigallocatechin gallate (EGCG), an inhibitor of
GLUD1 [27] for 48 h and then exposed them to ß-lap.
Consistent with our RNAi results (Fig. 2i), we found that
GLUD1 inhibition by EGCG had no effect on ß-lap sensi-
tivity (Fig. 3b). Furthermore, normal human IMR-90 em-
bryonic lung fibroblasts, which have low NQO1 levels [26]
were not affected by ß-lap, with or without BPTES treat-
ments (Fig. 3c). Replenishing the NADPH-producing
transamination pathway with the addition of OAA or
dimethyl malate, metabolites downstream of GLS1,
rescued BPTES-dependent hypersensitivity to ß-lap in
MiaPaCa2, ASPC1, and HPAFII PDA cells (Fig. 3d).
Mutant KRAS signaling drives NQO1 expression and
glutamine dependence [7, 8, 28, 29], thus we sought to
assess the generality of mutant KRAS expression on the
effects of BPTES and ß-lap. BPTES pre-treatment sensi-
tized a variety of NQO1-expressing KRAS mutant cancer
cell lines to ß-lap, including lung, triple-negative breast,
and additional PDA cell lines. In contrast, NQO1-defi-
cient KRAS mutant lines remained resistant to ß-lap,
whether or not BPTES was added (Fig. 3e). In addition,
pre-treatment with 500 nM BPTES for 48 h did not
increase the sensitivities of ß-lap-responsive, NQO1-
expressing KRAS wild-type lung, breast, or pancreatic
cancer cell lines, consistent with reported literature
[8, 30]. Collectively, these results illustrate that in
order for this targeted combination of agents to be
effective, sensitive cells must exhibit both mutant
KRAS-driven Gln dependence and NQO1 expression.
The latter is a feature of most, but not all, mutant
KRAS-transformed cancer types.
Fig. 3 GLS1 inhibition by BPTES sensitizes PDA to ß-lap in an NQO1-dependent manner. a Clonogenic survival assay of MiaPaCa2 pre-treated
± 500 nM BPTES for 48 h followed by the addition of ß-lap ±50 μM for 2 h. Data represent survival means ± SE from quadruplicate samples.
b MiaPaCa2 cells treated with 100 μM of the GLUD1 inhibitor, EGCG, for 48 h followed by 2-h ß-lap dose response. Relative cell viability represents
mean of CellTiter-Glo survival assay 48 h after ß-lap treatment plotted as percentage treated/control (T/C) ± SE from sextuplicate samples. c Clonogenic
survival assay of normal lung fibroblast cell line, IMR90, pre-treated with ±500 nM BPTES for 48 h followed by 2 h of ß-lap treatment. Data represent
survival means ± SE from quadruplicate samples. d MiaPaCa2, ASPC1, and HPAFII PDA cell lines were pre-treated with ± 500 nM BPTES for 48 h,
either 3 mM oxaloacetate (OAA) or 3 mM dimethyl malate for the last 24 h, and 2.5 μM ß-lap for 2 h. Relative cell viability represents means of
CellTiter-Glo survival assay 48 h after treatment plotted as percentage (T/C) ± SE from sextuplicate samples. e Various cancer cell lines pre-treated with
± 500 nM BPTES (sub-growth inhibitory) for 48 h followed by the addition of 2.5 μM ß-lap for 2 h. Mutant (mt) KRAS lines: A549 non-small cell lung
(NSCL), PL45 PDA, NQO1 expressing S2-013 (S2+) PDA, NQO1 expressing MDA-MB-231 (231+) triple-negative breast, H2122 NSCL, NQO1-deficient
S2-013 (S2−) PDA, and NQO1 deficient MDA-MB-231 (231−) triple-negative breast cancer cells. Wild-type (wt) KRAS lines: Hs766T PDA, BxPC3
PDA, MCF7 breast, as well as NQO1+ H596 NSCL and H661 NSCL cancer cell lines
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GLS1 inhibition attenuates anti-oxidant defenses and
increases susceptibility to ß-lap-induced DNA damage
We observed a dose-dependent increase in NADP
+/NADPH ratios, a proxy for the cell’s oxidative state, in
MiaPaCa2 cells exposed to ß-lap alone, reaching fourfold
higher levels versus baseline found in untreated cells
(Fig. 4a). With BPTES pre-treatment, we noted a sevenfold
increase in NADP+/NADPH ratios in ß-lap-exposed cells
versus baseline levels in untreated MiaPaCa2 cells (Fig. 4a)
and an ~twofold higher level than in cells exposed to ß-lap
alone. BPTES pre-treatment (500 nM, 48 h) also signifi-
cantly lowered reduced glutathione (GSH) levels in Mia-
PaCa2 cells compared to DMSO vehicle alone (>twofold;
Additional file 3: Figure S3A), and extracellular H2O2 pro-
duction was dramatically increased after BPTES plus ß-lap
treatment in a time- and dose-dependent manner (Fig. 4b,
Additional file 3: Figure S3B). Additionally, total intracellu-
lar ROS levels were dramatically increased after BPTES
plus ß-lap treatment (Additional file 3: Figure S3C). Con-
sistent with the kinetics of H2O2 production, we observed a
decrease in the minimum time to death [31, 32] for ß-lap-
induced lethality in MiaPaCa2 with BPTES pre-treatment
(Fig. 4c). This effect on clonogenic survival could be
rescued with the anti-oxidant reduced diethyl-ester
GSH in ß-lap-exposed MiaPaCa2, ASPC1, HPAFII, and
MPanc96 cells after 48 h pre-treatment with BPTES
plus 2 h with ß-lap (Fig. 4d).
Pre-treatment with BPTES followed by exposure to ß-
lap synergistically increased total DNA lesions in ASPC1
cells, as assessed by alkaline comet assay immediately after
Fig. 4 GLS1 inhibition decreases anti-oxidant defenses and increases susceptibility to ß-lap-induced DNA damage. a Relative NADP+ to NADPH ra-
tio in MiaPaCa2 cells pre-treated with BPTES for 48 h (500 nM) and then treated with ß-lap for 2 h. NADP+ and NADPH levels were measured im-
mediately after 2 h treatment. b Relative extracellular H2O2 was measured through luminescence assay from the media of 4 μM ß-lap ± DIC,
±BPTES-treated MiaPaCa2 over a time-frame of 120 min, ±SE from sextuplicate samples. c Clonogenic survival of MiaPaCa2 pre-treated ± 500 nM
BPTES for 48 h followed by the addition of ß-lap for various incubation times. Data represent survival means ± SE from quadruplicate samples.
d MiaPaCa2, ASPC1, HPAFII, and MPanc96 pre-treated with ±500 nM BPTES and ±GSH reduced ethyl ester for 48 h followed by the addition of
ß-lap for 2 h. e, f Alkaline comet assay of ASPC1 PDA cell lines pre-treated with ±500 nM BPTES followed by 2 h of ß-lap. g Average 53BP1 foci
24 h post treatment in MiaPaCa2. h Western blot for PAR formation with indicated treatment after 15 min of ß-lap exposure. i Relative NAD+ levels
±BPTES with various doses of ß-lap after 2 h of treatment. All results were compared using Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.001
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2-h treatment, and DNA double-strand break (DSB) for-
mation in MiaPaCa2 cells, monitored by 53BP1 foci for-
mation 24 h after treatment (Figs. 4e–g). Furthermore,
pre-treatment with BPTES followed by treatment with ß-
lap dramatically increased PARP hyperactivation noted by
concomitant NAD+ depletion and PAR formation, which
was blocked with the addition of the PARP inhibitor,
Rucaparib (AG014699), in MiaPaCa2 cells compared to ei-
ther treatment alone (Fig. 4h, i). These data indicate that
PDA cells are reliant on glutamine for redox balance and
that the disrupted redox state enhances ß-lap-induced
DNA damage and PARP-driven metabolic catastrophe.
GLS1 inhibition sensitizes PDA to ß-lap in vivo
To determine whether pharmacologic inhibition of GLS1
in combination with ß-lap would lead to synergistic in-
hibition of PDA tumor growth in vivo, we utilized the
clinical formulation of ß-lap (ARQ761), hydroxypropyl
beta cyclodextrin travel (HPßCD)-ß-lap, and the orally
available GLS1 inhibitor, CB-839, provided by Calithera
Biosciences. Both compounds are in separate phase I/II
clinical trials for a variety of cancer types (NCT01502800,
NCT02071862, NCT02071888, and NCT02071927) [11].
CB-839 was employed for these studies because BPTES
has poor metabolic stability and low solubility in vivo [11].
First, we confirmed that CB-839 pre-treatment, like
BPTES, also sensitized PDA cell lines in vitro to ß-lap in
the MiaPaCa2 and ASPC1 lines (Fig. 5a). Next, we gener-
ated subcutaneous tumors from human MiaPaCa2 cells
injected into the right hind limb in Nu/Nu female athymic
mice and allowed the tumors to grow to a volume of
100 mm3 before beginning treatment. The mice were sacri-
ficed when tumor volumes reached 1000 mm3, as per the
Institutional Animal Care and Use Committee (IACUC)
regulations.
The animals received either vehicle (i.e., HPßCD) or
CB-839 (200 mg/kg) by oral gavage twice a day for
10 days, with or without a sub-efficacious dose of ß-lap
(25 mg/kg) administrated intravenously (IV) every other
day (Fig. 5b, arrows) [33]. After only one regimen of
treatment (10 days), we found that the mice treated with
CB-839 plus ß-lap displayed significantly delayed tumor
growth compared to either agent alone through day 60.
Importantly, we noted that neither CB-839 (200 mg/kg)
Fig. 5 GLS1 inhibition sensitizes pancreatic cancer to ß-lap in vivo. a Clonogenic survival of MiaPaCa2 and ASPC1 cells pre-treated with 1 μM
CB-839 for 48 h followed by 2 h of ß-lap dose response. b Subcutaneous tumors grown from MiaPaCa2 cells in nude mice were allowed to reach
a volume of 100 mm3, after which, the mice were treated every other day with vehicle (HPßCD, n = 6), sub-efficacious dose of CB-839 (oral gavage,
200 mg/kg, twice daily for 10 days, n = 8), sub-efficacious dose of ß-lap (IV, 25 mg/kg, n = 8) or sub-efficacious doses of CB-839 and ß-lap (n = 10) for a
total of five doses (arrows). Tumor growth was monitored until tumors reached 1000 mm3. Error bars, SEM. c Survival of tumor-bearing mice
represented as a Kaplan–Meier plot. The mice were sacrificed when tumors reached 1000 mm3. Statistically analyzed with the log-rank test
for trend. d Western blot of PAR and γH2AX from a set of tumors harvested 30 min after treatment with ß-lap ± CB-839 (4-day treatment),
n = 3 tumors per group, same doses as above. e Relative GSH/GSSG ratio in treated groups normalized to microgram of tumor protein.
Unless stated otherwise, all results were compared using Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.001
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nor ß-lap (25 mg/kg) administered alone significantly
altered tumor growth (Fig. 5b). Individual tumors are
presented in waterfall plots in Additional file 4: Figure
S4A. Notably, combination treatment did not decrease
mouse weights when compared to vehicle-treated mice
(Additional file 4: Figure S4B). Long- or short-term toxic-
ities, including hemolysis and methemoglobinemia, were
not observed.
The mice were sacrificed when their original body
weights dropped by one third, tumor volumes exceeded
1000 mm3, or when tumors began to ulcerate or impede
normal motion. Kaplan–Meier curves showed a signifi-
cant anti-tumor effect of the drug combination (Fig. 5c).
The treatment with a sub-efficacious dose of ß-lap
(25 mg/kg) resulted in a median survival of 49 days, while
the vehicle-treated group displayed a median survival time
of 39.5 days (Fig. 5c). The treatment with a sub-efficacious
dose of CB-839 resulted in a median survival time of
42 days. The treatment with the ß-lap plus CB-839 com-
bination resulted in a median survival of 64 days,
significantly extending median survival by 24.5 days com-
pared to the vehicle (HPßCD)-treated group (Fig. 5c).
Importantly, to ensure that the anti-tumor efficacy we
observed was due to on-target effects of both drugs and
by the same mechanism of action observed in vitro, we
analyzed the pharmacodynamics profile of each agent
alone and in combination. Briefly, the MiaPaCa2 tumor-
bearing mice received either vehicle (HPßCD) alone or
200 mg/kg CB-839 by oral gavage twice a day for 4 days,
with or without a single sub-efficacious dose of ß-lap at
25 mg/kg IV on day 4. After the last dose of CB-839 and
30 min after ß-lap injection, the mice were sacrificed and
the tumor tissue was harvested. Tumor glutamate levels
were measured from multiple animals for each treatment
condition (Additional file 4: Figure S4C). CB-839 and CB-
839 plus ß-lap-treated mice displayed significantly lower
overall tumor glutamate levels when compared to vehicle
or ß-lap alone treatments, consistent with GLS1 inhibition
in vivo (Additional file 4: Figure S4C).
We then immunoblotted tumor tissue lysates for PAR
polymer formation as a proxy for PARP hyperactivity and
γH2AX to assess DNA DSBs (Fig. 5d, see quantification in
Additional file 4: Figure S4D) [33]. Consistent with our re-
sults in vitro, we found that the mice treated with the
combination of ß-lap plus CB-839 displayed dramatically
increased PAR and γH2AX formation relative to all other
groups (Fig. 5d). Additionally, we harvested liver tissue
(“normal tissue” in Fig. 5d) from the mice after exposure
to the combination-treated mice and found no evidence
of PAR or γH2AX formation (Fig. 5d), consistent with a
lack of response to ß-lap in normal tissues [24, 33]. Not-
ably, the liver contains the highest levels of NQO1 in the
mouse (not in human livers) and is used as a surrogate for
normal tissue responses to NQO1-bioactivatable drugs.
Next, to determine the redox status of tumors after
treatment, we measured the GSH to glutathione disul-
fide (GSSG) ratio of tumor lysates after vehicle alone
or CB-839, with or without 30-min ß-lap treatment.
Interestingly, we found that the GSH to GSSG ratios
were significantly decreased in the single-arm CB-839
or ß-lap-treated mice (Fig. 5e). Moreover, the combin-
ation treatment resulted in an even greater decrease in
GSH, monitored by the GSH to GSSG ratio (Fig. 5e).
Taking our pharmacodynamics observations and anti-
tumor studies together, these data demonstrate that
modulating glutamine metabolism in PDA in vivo re-
sults in a significantly decreased anti-oxidant defense
state. As a result, the drug combination significantly
sensitized NQO1-expressing tumors, but not associ-
ated normal tissue, to ROS induction from ß-lap lead-
ing to DNA damage, PARP hyperactivation, and
tumor-selective death.
Discussion
Tumor cells display unique metabolic alterations that
impact the biological behavior of the tumor and have
therapeutic implications [34, 35]. A well-documented ex-
ample of such an alteration is the increased utilization of
glutamine in a variety of human tumors, including lung,
prostate, lymphoma, and PDA [8, 15, 36, 37]. Glutamine
has pleiotropic roles in the cell that include the regula-
tion of autophagy, signal transduction, anabolic growth,
and redox balance [9]. In PDA, mutant KRAS promotes
the reprogramming of glutamine metabolism through a
GOT1- and GOT2-mediated transamination pathway in-
stead of the pathway catalyzed by GLUD1 [8]. This trans-
amination pathway is necessary to maintain redox balance
in PDA tumors through maintenance of reduced NADPH
and GSH levels (Fig. 1a) [2, 8, 9]. While this understanding
provides insight into PDA metabolism, how to most appro-
priately exploit this metabolic vulnerability had remained to
be determined. Previous work revealed that targeting this
pathway alone resulted in cytostasis, driving compensatory
metabolic resistance pathways in the tumor. In addition,
potential systemic toxicities remain to be determined.
Genes involved in the glutamine-dependent transamin-
ation pathway (GLS1, GOT1/2, ME1) and NQO1, but not
GLUD1, are highly expressed in PDA relative to other
cancers (Fig. 1b). Clinical PDA cases expressing a high
GOT1 to GLUD1 or GOT2 to GLUD1 ratio in the
tumor have worse outcomes (Fig. 1c, Additional file 1:
Figure S1B). Here, we found that genetic or pharmaco-
logical inhibition of this pathway sensitizes PDA to the
NQO1-bioactivatable drug, ß-lap. Addition of ß-lap in
combination with GLS1 inhibition resulted in en-
hanced tumor-cell specificity and efficacy in PDA cell
lines, not typically found with GLS1 inhibition alone.
Consistent with prior reports of differential usage of
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glutamine in mutant KRAS versus wild-type KRAS can-
cers [4, 8, 30, 38], we found that mutant KRAS cell
lines, but not wild-type KRAS PDA, lung, and breast
cancer, were sensitized to ß-lap upon pre-treatment
with BPTES. These data suggest that mutant, compared
to wild-type, KRAS cancers may also rely on glutamine to
maintain redox balance, though this may not necessarily
involve the transamination pathway discussed. Future
studies to elucidate this mechanism will be needed.
When considering the ROS burst generated from
NQO1-bioactivatable drugs, as evidenced by ß-lap’s H2O2
production profile, cells require an equally robust anti-
oxidant response to suppress ROS accumulation. Thus,
one can imagine that a competition between the rates of
engagement of the anti-oxidant machinery and the pro-
duction of ROS determines the fate of cancer cells within
a tumor following NQO1-bioactivatable drug treatment.
Notably, we previously reported that catalase (an essential
enzyme for the detoxification of 2H2O2 to 2H2O +O2) ex-
pression was significantly downregulated in tumor tissue
relative to normal tissue, and that the NQO1 to catalase
ratio is markedly increased in tumor tissue. Moreover,
addition of PEGylated catalase significantly protected
breast cancer cell lines from ß-lap-induced lethality [25].
To maintain redox balance, PDA may utilize glutamine
metabolism to compensate for this decrease in catalase.
Indeed, addition of BPTES to NQO1-overexpressing
cancer cells decreased NADPH and GSH anti-oxidant
defenses, which would otherwise counteract the ß-lap-
induced ROS burst and thus lead to enhanced DNA
damage, PARP-driven NAD+ and ATP depletion, and
metabolic catastrophe. Mechanistically, this occurred in a
near-identical manner to the caspase-independent, μ-
calpain-mediated cell death pathway induced by lethal
doses of ß-lap alone [39], only at lower doses, which act to
augment the therapeutic window for ß-lap.
For our in vivo studies, we utilized the GLS1 inhibitor
CB-839, as this compound has far greater solubility and
stability in animals than BPTES [11]. A single regimen
of CB-839 plus ß-lap in the tumor-bearing mice slowed
tumor progression and significantly improved survival
compared to the animals treated with either agent alone.
Pharmacodynamics analysis revealed that the mechan-
ism of synergy with combination treatment in vivo was
consistent with the in vitro results. In sum, these results
are promising but preliminary in nature, given their reliance
on subcutaneous PDA cell line-derived xenografts, as these
models may overestimate the efficacy of therapeutic regi-
mens [40]. Future work will test combination treatment
regimens in genetically engineered PDA mouse models
[41]. We should note, however, that subcutaneous xeno-
graft models do represent a challenging microenvironment
for pancreatic cancer studies due to the hypoxic environ-
ment and limited blood supply.
Conclusions
Novel therapies are desperately needed for patients with
PDA. By combining GLS1 inhibition (e.g., CB-839) and
NQO1-bioactivatable drugs (e.g., β-lap, ARQ761), we
exploit the reliance of PDA on glutamine for redox bal-
ance, as well as the tumor-selective overexpression of
NQO1 through the use of a unique agent that is bioacti-
vated to induce cell death. Combination treatment with
GLS1 inhibitors plus ß-lap addresses limitations asso-
ciated with either agent alone. Namely, this combin-
ation is expected to enhance efficacy at well-tolerated
doses of these drugs; the concentrations used in this
study are relevant to those that are achievable in pa-
tients (NCT01502800, NCT02071862, NCT02071888,
and NCT02071927) [11, 42]. Furthermore, we noted
that CB-839 plus ß-lap combination-treated animals
did not display increased cytotoxicity in normal liver
tissue, based on a lack of PAR and DNA damage for-
mation. These results reinforce the necessity for NQO1
expression to achieve cell death. Collectively, these find-
ings illustrate a rational combination strategy to target
PDA dependence on glutamine, by GLS1 inhibition, in
combination with an NQO1-bioactivatable drug and pro-
vide the proof-of-concept validation to warrant analysis in
a larger pre-clinical context.
Methods
Cell culture
A549, MiaPaCa2, DAN-G, SW1990, MPanc96, SUIT2-
013-NQO1+/−, HPAFII, ASPC1, PL45, H596, Hs766T,
BxPC3, MBA-MD-231+/−, and MCF7 cell lines were
obtained from ATCC, tested for mycoplasma contamin-
ation and grown in complete Dulbecco's Modified
Eagle's Medium (DMEM) with 10 % fetal bovine serum
(FBS). H2122 and H661 cell lines were a generous gift
from Dr. John Minna at UTSW. SUIT2-013 and MDA-
MB-231 NQO1 deficient and proficient cell lines were
generated as previously described [24]. DMEM (glutamine
free) was purchased from Sigma-Aldrich. FBS was pur-
chased from Fischer Scientific. Glutamine, GSH-reduced
ethyl ester, OAA, and dimethyl malate were purchased
from Sigma. IMR90 cells lines were grown in MEM with
10 % FBS. All cells were incubated at 37° with 5 % CO2.
Reagents and chemicals
ß-Lap was synthesized, purified, and prepared at 50 mM
stock solution as previously described [18]. BPTES and
DIC were purchased from Sigma-Aldrich (St Louis, MO).
CB-839 was kindly provided by Calithera Biosciences (San
Francisco, CA).
Survival assays
For clonogenic survival assays, the cells were plated in
10-cm plates at 2 × 105 cells per plate and pre-treated
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with ±BPTES for 48 h, then treated with the appropriate
ß-lap doses for 2 h. The cells were then trypsinized and
plated onto six-well plates at 100, 500, or 1000 cells per
well in 2 mL of complete media. After 7 days of prolifera-
tion, the plates were washed in PBS and colonies were
fixed in methanol/crystal violet; all clonogenic assay re-
sults are represented as % Survival (treated/control, T/C).
Cell viability was also assessed using the CellTiter-Glo
assay (Promega). The cells were plated and pre-treated
with ±BPTES as described above. The cells were then
plated at 6 × 104 cells per well in a 96-well plate in 100 μL
of media. The following day, the cells were treated with
the appropriate doses of ß-lap for 2 h, and then ATP levels
were checked 48 h after treatment; cell viability is repre-
sented as Relative Cell Viability % (T/C). Relative cell sur-
vival was also assessed using 7-day DNA assays as
previously described and reported as Relative Survival %
(T/C) [43]. Results are reported as means ± standard error
(SE) from at least three independent experiments done in
sextuplicate. This dose of ß-lap (4 μM, 2 h) typically
yields 80–90 % lethality in MiaPaCa2 cell lines across
these assays.
Glutathione, NAD(P)H, H2O2, and total ROS assays
The following assays were purchased from Promega:
GSH/GSSG-Glo, NAD/NADH-Glo, NADP/NADPH-Glo,
and ROS-Glo and were used as instructed by the manu-
facturer. The total intracellular ROS levels were detected
using the cell-permeable fluorogenic probe CellROX®
(Molecular Probes) that emits red fluorescence upon oxi-
dation by ROS. Briefly, the cells were incubated with
5 μM CellROX® and ß-lap for 30 min at 37 °C followed by
fixation in 4 % paraformaldehyde. ROS generation was an-
alyzed by flow cytometry.
siRNA knockdown
siRNA was transiently transfected into the cells using
Opti-MEM and Lipofectamine RNAiMAX for 48 h (Life
Technologies) for the following enzymes: GLS1, ON-




3′; and GOT2, 5′GCCUUUAAGAGGGACACCA-3′. All
siRNAs were purchased from Sigma. After 48 h of incuba-
tion, the cells were detached with trypsin/EDTA (Life
Technologies) and seeded for treatment assays or lysed for
analysis of knockdown efficiency. Growing cells in Opti-
MEM and Lipofectamine for 48 h increased their sensitiv-
ity to ß-lap in the siScr group alone.
Western blot
Western blots were carried out as previously described
[25]. Primary antibodies for protein detection included:
GLS1 (ab93434, Abcam), PARP1 (F-2, Santa Cruz), PAR
(Trevigen, Gaithersburg, MD), Actin (C-2, Santa Cruz),
small subunit calpain (EPR3324, Abcam), and 53BP1
(Bethyl Laboratories).
Human xenograft anti-tumor, pharmacodynamics assays
The athymic Nu/Nu nude female mice (18–20 g) were
commercially obtained (Harlan). Human xenografts
were generated by injecting 2 × 106 MiaPaCa2 cells sub-
cutaneously in PBS/Matrigel into 6-week-old mice. The
tumors were measured at indicated times with digital
calipers (Fisher Scientific), and tumor volumes calcu-
lated (length × width2 × 0.5). The treatments were initi-
ated when subcutaneous tumors reached an average size
of ≥100 mm3. The mice were treated with CB-839 by
oral gavage, ß-lap (as HPßCD-ß-lap) by IV (retro-or-
bital) or both or with vehicle (HPßCD; 1:9, v/v; Sigma-
Aldrich) as a control. The treatment regimens consisted
of a total of five doses of ß-lap, with one dose being
administered every other day for 10 days. CB-839 was
administered twice a day, everyday for 10 days. The
mice bearing subcutaneous tumors were treated with
nontoxic doses (200 mg/kg) of CB-839, with or without
a sub-efficacious dose of HPßCD-ß-lap (25 mg/kg). The
mice bearing subcutaneous tumors were sacrificed when
tumors reached >1000 mm3 as per IACUC. Overall sur-
vival was assessed through Kaplan–Meier curves using the
log-rank test for trend for statistical significance. The mice
were weighed three times per week during and after the
drug treatment period with no toxicities observed. All ani-
mal studies were performed in accordance under proto-
cols approved by the Institutional Animal Care and Use
Committee of UT Southwestern Medical Center.
Statistics
All graphs are plotted as mean with error bars denoting
standard deviation. Regression analysis, ANOVA, and two-
tailed Student t tests for statistical significance with Holm/
Sidak multiple comparison correction were performed in
GraphPad Prism 6. p values were expressed throughout by
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Additional files
Additional file 1: Figure S1. ß-Lap mechanism and GOT2 to GLUD1
Kaplan–Meier curve. (A) ß-lap mechanism of action. In the cytosol of
cancer cells, one equivalent of β-lap undergoes a futile redox cycle with
NQO1 to produce ~120 equivalents of H2O2, in 2–5 min (depending
on cancer cell), which results in DNA damage, PARP1 hyperactivation,
NAD+ and ATP depletion, and ultimately caspase-independent apoptosis
(a form of cell death known as programmed necrosis). NAD, nicotinamide
adenine dinucleotide; NADPH, nicotinamide adenine dinucleotide
phosphate (reduced); NQO1, NADPH:quinone oxidoreductase; PARP1,
poly(ADP ribose) polymerase 1. (B) GOT2 to GLUD1 Kaplan–Meier
curve, n = 45 patients.
Chakrabarti et al. Cancer & Metabolism  (2015) 3:12 Page 10 of 12
Additional file 2: Figure S2. BPTES sensitivity. (A) Growth inhibition in
MiaPaCa2 cells, as monitored by loss of ATP, to short-term (48 h) or
long-term (96 h) BPTES treatments.
Additional file 3: Figure S3. Combination treatment leads to increased
ROS by depleting reduced glutathione. (A) Relative GSH levels ±500 nM
BPTES pre-treatment followed by ß-lap treatment. (B) Relative H2O2 production
with ±500 nM BPTES pre-treatment followed by ß-lap treatment. (C) CellROX®
quantification of total ROS at 15 min of ±4 μM ß-lap, ±DIC, and ±BPTES (48-h
pre-treatment).
Additional file 4: Figure S4. Assessment of drug effects on PDA tumors
and animals. (A) Change in tumor volumes per animal at day 22 compared
to day 1. (B) Mouse weights during treatment for vehicle (n = 6),
CB-839 (n = 8), ß-lap (n = 8) and ß-lap plus CB-839 (n = 10). (C) Tumor
glutamate levels, n = 3 mice per group. (D) Quantification of relative
PAR and γH2AX from tumor tissue lysate according to the western
blot in Fig. 5d.
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